| Gregory D Whiteman, MD | |
|
2024 S 6th St, Brainerd, MN 56401-3054 | |
| (218) 828-7100 | |
| (608) 781-1169 |
| Full Name | Gregory D Whiteman |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 31 Years |
| Location | 2024 S 6th St, Brainerd, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154311660 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 49885 (Minnesota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Good Samaritan Society Home Care & Hospice | Nisswa, MN | Home health agency |
| Essentia Health St Joseph's Medical Center | Brainerd, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| St Josephs Medical Center | 8224948443 | 215 |
News Archive
Chronic fatigue syndrome (CFS) is a potentially long-lasting illness that can cause considerable distress and disability. Some estimates suggest it may affect as many as 1 in 100 of the population globally.
BASF today announced that the Environmental Protection Agency (EPA) has approved the use of Aseptrol® S10 - Tab in H1N1 sanitization operations in institutional and industrial facilities, such as, schools, hospitals, government buildings, retail and restaurants, and recreational facilities. Aseptrol S10 - Tab is based on Chlorine dioxide (CIO2) release technology.
Revised guidelines for lung cancer screening eligibility are perpetuating disparities for racial/ethnic minorities, according to a new study in Radiology.
The use of radiofrequency ablation-targeted heat from an electrical current to ease nerve pain-may be helpful for treating chronic neck pain, but only in patients meeting particular criteria, conclude evidence-based consensus guidelines, published online in the journal Regional Anesthesia & Pain Medicine.
Alexion Pharmaceuticals, Inc. has announced today that Soliris® (eculizumab), its first-in-class complement inhibitor, has been granted Orphan Medicinal Product Designation by the European Commission for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). AHUS is an ultra-rare, inherited, and life-threatening complement-inhibitor deficiency disease that often progresses to end-stage kidney disease or failure. The U.S. Food and Drug Administration granted orphan drug designation to Soliris for the same indication in May 2009. Soliris is not approved for the treatment of patients with aHUS.
› Verified 7 days ago
| Entity Name | St Josephs Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568415974 PECOS PAC ID: 8224948443 Enrollment ID: O20031119000468 |
News Archive
Chronic fatigue syndrome (CFS) is a potentially long-lasting illness that can cause considerable distress and disability. Some estimates suggest it may affect as many as 1 in 100 of the population globally.
BASF today announced that the Environmental Protection Agency (EPA) has approved the use of Aseptrol® S10 - Tab in H1N1 sanitization operations in institutional and industrial facilities, such as, schools, hospitals, government buildings, retail and restaurants, and recreational facilities. Aseptrol S10 - Tab is based on Chlorine dioxide (CIO2) release technology.
Revised guidelines for lung cancer screening eligibility are perpetuating disparities for racial/ethnic minorities, according to a new study in Radiology.
The use of radiofrequency ablation-targeted heat from an electrical current to ease nerve pain-may be helpful for treating chronic neck pain, but only in patients meeting particular criteria, conclude evidence-based consensus guidelines, published online in the journal Regional Anesthesia & Pain Medicine.
Alexion Pharmaceuticals, Inc. has announced today that Soliris® (eculizumab), its first-in-class complement inhibitor, has been granted Orphan Medicinal Product Designation by the European Commission for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). AHUS is an ultra-rare, inherited, and life-threatening complement-inhibitor deficiency disease that often progresses to end-stage kidney disease or failure. The U.S. Food and Drug Administration granted orphan drug designation to Soliris for the same indication in May 2009. Soliris is not approved for the treatment of patients with aHUS.
› Verified 7 days ago
| Entity Name | Brainerd Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295801777 PECOS PAC ID: 0648270272 Enrollment ID: O20070105000140 |
News Archive
Chronic fatigue syndrome (CFS) is a potentially long-lasting illness that can cause considerable distress and disability. Some estimates suggest it may affect as many as 1 in 100 of the population globally.
BASF today announced that the Environmental Protection Agency (EPA) has approved the use of Aseptrol® S10 - Tab in H1N1 sanitization operations in institutional and industrial facilities, such as, schools, hospitals, government buildings, retail and restaurants, and recreational facilities. Aseptrol S10 - Tab is based on Chlorine dioxide (CIO2) release technology.
Revised guidelines for lung cancer screening eligibility are perpetuating disparities for racial/ethnic minorities, according to a new study in Radiology.
The use of radiofrequency ablation-targeted heat from an electrical current to ease nerve pain-may be helpful for treating chronic neck pain, but only in patients meeting particular criteria, conclude evidence-based consensus guidelines, published online in the journal Regional Anesthesia & Pain Medicine.
Alexion Pharmaceuticals, Inc. has announced today that Soliris® (eculizumab), its first-in-class complement inhibitor, has been granted Orphan Medicinal Product Designation by the European Commission for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). AHUS is an ultra-rare, inherited, and life-threatening complement-inhibitor deficiency disease that often progresses to end-stage kidney disease or failure. The U.S. Food and Drug Administration granted orphan drug designation to Soliris for the same indication in May 2009. Soliris is not approved for the treatment of patients with aHUS.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Gregory D Whiteman, MD 523 N 3rd St, Brainerd, MN 56401-3054 Ph: (218) 829-2861 | Gregory D Whiteman, MD 2024 S 6th St, Brainerd, MN 56401-3054 Ph: (218) 828-7100 |
News Archive
Chronic fatigue syndrome (CFS) is a potentially long-lasting illness that can cause considerable distress and disability. Some estimates suggest it may affect as many as 1 in 100 of the population globally.
BASF today announced that the Environmental Protection Agency (EPA) has approved the use of Aseptrol® S10 - Tab in H1N1 sanitization operations in institutional and industrial facilities, such as, schools, hospitals, government buildings, retail and restaurants, and recreational facilities. Aseptrol S10 - Tab is based on Chlorine dioxide (CIO2) release technology.
Revised guidelines for lung cancer screening eligibility are perpetuating disparities for racial/ethnic minorities, according to a new study in Radiology.
The use of radiofrequency ablation-targeted heat from an electrical current to ease nerve pain-may be helpful for treating chronic neck pain, but only in patients meeting particular criteria, conclude evidence-based consensus guidelines, published online in the journal Regional Anesthesia & Pain Medicine.
Alexion Pharmaceuticals, Inc. has announced today that Soliris® (eculizumab), its first-in-class complement inhibitor, has been granted Orphan Medicinal Product Designation by the European Commission for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). AHUS is an ultra-rare, inherited, and life-threatening complement-inhibitor deficiency disease that often progresses to end-stage kidney disease or failure. The U.S. Food and Drug Administration granted orphan drug designation to Soliris for the same indication in May 2009. Soliris is not approved for the treatment of patients with aHUS.
› Verified 7 days ago
Dr. Thomas E Applegate, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 523 N 3rd St, Brainerd, MN 56401 Phone: 218-828-2861 | |
Heidi L Malling, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 523 N 3rd St, Brainerd, MN 56401 Phone: 218-829-2861 | |
Dale Hadland, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2024 S 6th St, Brainerd, MN 56401 Phone: 218-828-7100 | |
James Gelbmann, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 523 N 3rd St, Medical Staff Office, Brainerd, MN 56401 Phone: 218-828-7100 | |
David Boran, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2024 S 6th St, Brainerd, MN 56401 Phone: 218-825-7100 | |
Susan Skarp, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 2024 S 6th St, Brainerd, MN 56401 Phone: 218-855-5431 |